Vaccinia DynPort Vaccine Company LLC - Treatment for Complications of Smallpox Vaccination
Vaccinia Immune Globulin Intravenous (VIGIV) is the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.Posted: February 2005
Related Articles:
Vaccinia (vaccinia immune globulin intravenous (human)) FDA Approval History

